Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate:An Interrupted Time Series Study

Autor: Abtahi, Shahab, Pajouheshnia, Romin, Durán, Carlos E, Riera-Arnau, Judit, Gamba, Magdalena, Alsina, Ema, Hoxhaj, Vjola, Andersen, Morten, Bartolini, Claudia, Kristiansen, Sarah Brøgger, Brown, Jeremy, Hallgreen, Christine Erikstrup, Garcia-Poza, Patricia, Gardarsdottir, Helga, Gini, Rosa, Girardi, Anna, Holthuis, Emily, Huerta, Consuelo, Ibánez, Luisa, Limoncella, Giorgio, Martín-Pérez, Mar, Paoletti, Olga, Roberto, Giuseppe, Souverein, Patrick, Swart, Karin M A, Wing, Kevin, Sturkenboom, Miriam, Klungel, Olaf

Publikováno v: Abtahi, S, Pajouheshnia, R, Durán, C E, Riera-Arnau, J, Gamba, M, Alsina, E, Hoxhaj, V, Andersen, M, Bartolini, C, Kristiansen, S B, Brown, J, Hallgreen, C E, Garcia-Poza, P, Gardarsdottir, H, Gini, R, Girardi, A, Holthuis, E, Huerta, C, Ibánez, L, Limoncella, G, Martín-Pérez, M, Paoletti, O, Roberto, G, Souverein, P, Swart, K M A, Wing, K, Sturkenboom, M & Klungel, O 2023, ' Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate : An Interrupted Time Series Study ', Drug Safety, vol. 46, no. 7, pp. 689-702 . https://doi.org/10.1007/s40264-023-01314-3

Introduction: Due to established teratogenicity of valproates, the EU risk minimisation measures (RMMs) with a pregnancy prevention programme (PPP) for valproate were updated in March 2018. Objectives: To investigate the effectiveness of the 2018 EU

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6c036f9da3dd97fc9f75f3ad06083a17
https://curis.ku.dk/ws/files/357512580/s40264_023_01314_3.pdf

Hydroxyzine initiation following drug safety advisories on cardiac arrhythmias in the UK and Canada: a longitudinal cohort study

Autor: Morrow, Richard L, Mintzes, Barbara, Souverein, Patrick C, Hallgreen, Christine E, Ahmed, Bilal, Roughead, Elizabeth E, De Bruin, Marie L, Kristiansen, Sarah Brøgger, Lexchin, Joel, Kemp-Casey, Anna, Sketris, Ingrid, Mangin, Dee, Pearson, Sallie-Anne, Puil, Lorri, Lopert, Ruth, Bero, Lisa, Gnjidic, Danijela, Sarpatwari, Ameet, Dormuth, Colin R, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Drug Safety, 45(6), 623. Springer International Publishing Switzerland
Morrow, R L, Mintzes, B, Souverein, P C, Hallgreen, C E, Ahmed, B, Roughead, E E, De Bruin, M L, Kristiansen, S B, Lexchin, J, Kemp-Casey, A, Sketris, I, Mangin, D, Pearson, S A, Puil, L, Lopert, R, Bero, L, Gnjidic, D, Sarpatwari, A & Dormuth, C R 2022, ' Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada : A Longitudinal Cohort Study ', Drug Safety, vol. 45, pp. 623–638 . https://doi.org/10.1007/s40264-022-01175-2

Introduction: Regulatory advisories on hydroxyzine and risk of QT prolongation and Torsade de pointes (TdP) were issued in the UK in April 2015 and Canada in June 2016. We hypothesized patients with risk factors for QT prolongation and TdP, compared

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63b3e7847c02508705fa302408c302ec
https://hdl.handle.net/11541.2/31088

Role of pannexin and adenosine triphosphate (ATP) following myocardial ischemia/reperfusion.

Autor: Kristiansen, Sarah Brøgger^1,2, Skovsted, Gry Freja^1,3, Berchtold, Lukas Adrian^4,5, Radziwon-Balicka, Aneta¹, Dreisig, Karin¹, Edvinsson, Lars¹, Sheykhzade, Majid², Haanes, Kristian Agmund¹ kristian.agmund.haanes@regionh.dk

Publikováno v: Scandinavian Cardiovascular Journal. Dec2018, Vol. 52 Issue 6, p340-343. 4p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.